Iressa News and Research

RSS

Novel animal model of lung adenocarcinoma

Drs. Katerina Politi, Harold Varmus and colleagues at the Memorial Sloan Kettering Cancer Center in New York have developed a novel animal model of lung adenocarcinoma that will be of great use in testing the efficacy of targeted therapies against human lung cancer.

17 May 2006

Impact of a scientific presentation on community treatment patterns for primary breast cancer

The oral presentation of data from a single study at a national scientific conference can have an important impact on patient treatment, even before study publication or Food and Drug Administration (FDA) approval

15 Mar 2006

Genzyme launches test to monitor Gleevec resistance

Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).

13 Feb 2006

Mutated oncogene triggers aggressive breast cancer

Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment.

18 Jan 2006

Targeted cancer therapies: Another step forward

While it is clear that the treatment of cancer has already begun to undergo a paradigm shift with the inclusion of innovative targeted therapies into current regimens, it would be wrong to assume these products will entirely replace traditional chemotherapy as the standard treatment for cancer sufferers.

22 Dec 2005

Targeted cancer therapies: Another step forward

22 Dec 2005

Gene mapping project promises new targeted cancer therapies

Government researchers in the United States have this week launched a pilot project to find all the little genetic changes that cause cancer in the hope it will lead to a whole new world of targeted cancer therapy.

14 Dec 2005

Researchers can now identify patients likely to respond to cancer drug therapy

Researchers at UCLA's Jonsson Cancer have identified key characteristics in certain deadly brain tumors that make them 51 times more likely to respond to a specific class of drugs than tumors in which the molecular signature is absent.

13 Nov 2005

Mutations in the targets of designer drugs critically influence their effectiveness

Two designer cancer drugs differed dramatically in a laboratory test comparing their ability to shut down a mutant, overactive growth signal in lung cancer cells, reports a team headed by scientists at the Dana-Farber Cancer Institute.

18 Aug 2005

Researchers identify protein called EMP-1 that is present in the tumors of patients who fail to respond to treatment with gefitinib

By the time the human genome was mapped, cancer researchers had already begun investigating the proteins that were encoded by these newly identified genes.

9 Aug 2005

Researchers discover sections of the chromosomes of lung cancer cells where cancer-related genes may lurk

With equipment designed to probe the smallest segments of the genetic code, researchers at Dana-Farber Cancer Institute and collaborating institutions have found something much larger: sections of the chromosomes of lung cancer cells where cancer-related genes may lurk.

6 Jul 2005

DNA imaging suggests where lung cancer genes may reside

With equipment designed to probe the smallest segments of the genetic code, researchers at Dana-Farber Cancer Institute and collaborating institutions have found sections of the chromosomes of lung cancer cells where cancer-related genes may lurk.

4 Jul 2005

FDA severely limits access to cancer drug Iressa

After Food and Drug Administration (FDA) officials agreed with studies showing lung cancer drug, Iressa, did not help patients live longer, drug company AstraZeneca said it would severely limit access to its drug.

20 Jun 2005

AstraZeneca announces U.S. labeling change to Iressa (gefitinib tablets)

AstraZeneca has announced that after discussions with the U.S. Food and Drug Administration (FDA), the company is making a labeling change to Iressa (gefitinib tablets).

19 Jun 2005

Study examines biomarkers for response to erlotinib in glioma

Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).

14 Jun 2005

Gefitinib (Iressa) could reduce the size of breast cancer tumours

Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology.

17 May 2005

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Five-year data from a study evaluating the use of docetaxel (Taxotere) administered after cisplatin/etoposide chemotherapy plus radiation therapy demonstrate the best long-term survival rates reported in patients with locally advanced (Stage IIIB) non-small cell lung cancer (NSCLC).

16 May 2005

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be more likely to respond to the drug gefitinib (Iressa), and this high gene copy number may be an effective predictor of gefitinib efficacy, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Researchers at Fox Chase Cancer Center in Philadelphia have identified a subset of ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif.

20 Apr 2005

Clinical trial of gefitinib for advanced lung cancer closes early

Researchers have closed a randomized clinical trial comparing gefitinib (Iressa) vs. placebo following chemotherapy and radiation for patients with non-small cell lung cancer (NSCLC) that had spread only to nearby tissues or lymph nodes. Review of interim data indicated that gefitinib would not improve survival.

19 Apr 2005